65,437 trials
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival — 11.96; 10.78; 11.73; 10.87 Months — p=0.7428
Controlled Ovarian Stimulation · Infertility
Primary: The Oestradiol Concentration on the Day of Ovulation Induction — 11482; 12262 pmol/L
Neonatal Abstinence Syndrome
Primary: Length of Treatment With Opioid Medication — 19.1; 17.7 days
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 — 85.8; 81.6 percentage of participants
Hemostasis · Oral Contraceptive
Primary: Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels — 45.0; 56.8 pmol/L — p=0.5892
Acute Undifferentiated Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only) — 7.8 10^9 Neutrophils per Liter
Metastatic Prostate Cancer
Primary: Maximum Tolerated Dose (MTD) of Dasatinib Administered With Docetaxel — NA mg
Glycemic Index · Glycemic Response
Primary: Glycemic Response Measured as the Positive Incremental Area Under the Time-concentration Curve(iAUC) Calculated From Individual Glucose Measurements Upon Consumption of…
Cocaine Addiction · Cocaine-related Disorder · Executive Dysfunction
Primary: Abstinence — 71.4; 16.6 percentage of participants
Alcohol Dependence · Executive Dysfunction · Abnormal Craving for Drugs
Primary: Use of Alcohol — 15; 8 participants
Diffuse Large B-Cell Lymphoma
Primary: Complete Response (CR) Rate — 64.5; 63.5 percentage of participants — p=0.915
OHSS (Ovarian Hyperstimulation)
Primary: Frequency of Moderate to Severe OHSS. — 0; 2; 2; 0 participants
Anemia · Chronic Kidney Disease
Primary: Total Distance Walked or Wheeled in a Maximum of 10 Minutes at Each Visit — 210.0; 253.1; 210.0; 246.5 feet
Leukemia
Primary: Number of Participants Alive at Day 30 — 31; 39 Participants
Meibomian Gland Dysfunction
Primary: Meibomium Gland Dropout Score - Evidence of Meibomian Gland Dysfunction (MGD) Confirmed by Meibograhpy Imaging Using the Keratograph 4 Measured on a Subjective Grading…